Depletion of conventional CD4+ T cells is required for robust priming and dissemination of tumor antigen-specific CD8+ T cells in the setting of anti-CD4 therapy

Background Overcoming immune suppression is a major barrier to eliciting potent CD8+ T cell responses against cancer. Treatment with anti-CD4 monoclonal antibody is an effective means for eliminating CD4+Foxp3+ regulatory (Treg) cells in preclinical models and has also demonstrated efficacy in early...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Keisuke Shirai, Tiffany Chen, Mary Jo Turk, Delaney E Ramirez, Christo P C Dragnev, Tyler G Searles, Nathaniel Spicer, J Louise Lines, Aaron R Hawkes, Wilson L Davis, Asmaa Mohamed, Joseph D Phillips, Pamela C Rosato, Yina H Huang
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMJ Publishing Group 2024-11-01
Rangatū:	Journal for ImmunoTherapy of Cancer
Urunga tuihono:	https://jitc.bmj.com/content/12/11/e010170.full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!